Domov › Nemalicelični pljučni rak › Arizona › Tucson
Klinične študije za Nemalicelični pljučni rak v Tucson, AZ
17 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Tucson in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Vključevanje udeležencevFaza 3
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #1, Tucson
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- The University of Arizona Cancer Center - North Campus, Tucson
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Vključevanje udeležencevFaza 3
- Research Site, Tucson
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Vključevanje udeležencevFaza 3
- Southern Arizona VA Health Care System, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Vključevanje udeležencevFaza 1/2
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 3
- Research Site, Tucson
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Vključevanje udeležencevFaza 2/3
- Arizona Clinical Research Center, Tucson
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- The University of Arizona Cancer Center - North Campus, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- USOR Arizona Oncology Associates, Tucson
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Vključevanje udeležencevFaza 1/2
- University of Arizona Cancer Center, Tucson
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- University of Arizona, Tucson
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Vključevanje udeležencevFaza 1
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2/3
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
Vključevanje udeležencevVabljeni zdravi prostovoljci
- University of Arizona Cancer Center, Tucson
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site 111, Tucson
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Vključevanje udeležencevFaza 1
- The University of Arizona Cancer Center, Tucson
Študije za Nemalicelični pljučni rak v drugih mestih
- Houston, TX145 študij
- New York City, NY121 študij
- Arlington, VA104 študij
- Nashville, TN97 študij
- Boston, MA90 študij
- Los Angeles, CA87 študij
- St. Louis, MO73 študij
- Chicago, IL61 študij
- Baltimore, MD60 študij
- San Antonio, TX59 študij
- Columbus, OH57 študij
- Washington, DC55 študij
Druge študije v Tucson
- Rak dojke20 študij
- Debelost18 študij
- Prekomerna telesna teža15 študij
- Metastatski rak14 študij
- Rak (vse vrste)12 študij
- Srčno-žilne bolezni12 študij
- Kolorektalni rak11 študij
- Rak prostate11 študij
- Sladkorna bolezen tipa 211 študij
- Steatotična bolezen jeter10 študij
- Srčno popuščanje10 študij
- Visok krvni tlak10 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.